PMID- 34638273 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211016 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 19 DP - 2021 Sep 24 TI - Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. LID - 10.3390/cancers13194789 [doi] LID - 4789 AB - Large B-cell lymphomas (LBCL) are the most common types of non-Hodgkin lymphoma. Although outcomes have improved thanks to the introduction of rituximab-based chemoimmunotherapy, certain LBCL still represents a challenge because of initial resistance to therapy or recurrent relapses. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapies approved for patients with relapsed/refractory (R/R) LBCL, based on the results of phase II pivotal single-arm trials ZUMA-1 (for axi-cel) and JULIET (for tisa-cel). Here, we report patients outcomes with axi-cel and tisa-cel in the standard of care (SoC) setting for R/R LBCL, treated at our Institution. Data were collected from patients who underwent leukapheresis between August 2019 and February 2021. Toxicities were graded and managed according to the institution's guidelines. Responses were assessed as per Lugano 2014 classification. Of the 30 patients who underwent leukapheresis, 18 (60%) received axi-cel, while 12 (40%) tisa-cel. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 10% and 16% patients, respectively. Best objective and complete response rates were 73.3% and 40%, respectively. Treatment in SoC setting with CD19 CAR T-cell therapies for R/R LBCL showed a manageable safety profile and high objective response rate. FAU - Casadei, Beatrice AU - Casadei B AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. FAU - Argnani, Lisa AU - Argnani L AUID- ORCID: 0000-0003-4225-4626 AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. FAU - Guadagnuolo, Serafina AU - Guadagnuolo S AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. FAU - Pellegrini, Cinzia AU - Pellegrini C AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Stefoni, Vittorio AU - Stefoni V AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. FAU - Broccoli, Alessandro AU - Broccoli A AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. FAU - Nanni, Laura AU - Nanni L AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. FAU - Morigi, Alice AU - Morigi A AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. FAU - Lolli, Ginevra AU - Lolli G AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. FAU - Guarino, Maria AU - Guarino M AUID- ORCID: 0000-0002-8894-2187 AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, 40138 Bologna, Italy. FAU - Spinardi, Luca AU - Spinardi L AUID- ORCID: 0000-0002-5745-0315 AD - Diagnostic and Interventional Neuroradiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Pierucci, Elisabetta AU - Pierucci E AD - Dipartimento di Emergenza-Urgenza, Terapia Intensiva, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Fanti, Stefano AU - Fanti S AUID- ORCID: 0000-0003-1486-2624 AD - Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Bartoletti, Michele AU - Bartoletti M AD - Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy. FAU - Dicataldo, Michele AU - Dicataldo M AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Sabattini, Elena AU - Sabattini E AUID- ORCID: 0000-0002-4136-3591 AD - Hematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Bonifazi, Francesca AU - Bonifazi F AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. FAU - Zinzani, Pier Luigi AU - Zinzani PL AUID- ORCID: 0000-0002-2112-2651 AD - Istituto di Ematologia "Seragnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. AD - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, 40138 Bologna, Italy. LA - eng PT - Journal Article DEP - 20210924 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC8507677 OTO - NOTNLM OT - CAR T-cell therapy OT - large B-cell non-Hodgkin lymphoma OT - relapsed/refractory lymphoma COIS- The authors declare no conflict of interest. EDAT- 2021/10/14 06:00 MHDA- 2021/10/14 06:01 PMCR- 2021/09/24 CRDT- 2021/10/13 01:01 PHST- 2021/07/16 00:00 [received] PHST- 2021/09/21 00:00 [revised] PHST- 2021/09/22 00:00 [accepted] PHST- 2021/10/13 01:01 [entrez] PHST- 2021/10/14 06:00 [pubmed] PHST- 2021/10/14 06:01 [medline] PHST- 2021/09/24 00:00 [pmc-release] AID - cancers13194789 [pii] AID - cancers-13-04789 [pii] AID - 10.3390/cancers13194789 [doi] PST - epublish SO - Cancers (Basel). 2021 Sep 24;13(19):4789. doi: 10.3390/cancers13194789.